Sign inJoin waitlistJoin the waitlist

Nicholas McAndrew

Assistant Clinical Professor · UCLA David Geffen School of Medicine/UCLA Medical Center

Credentials: · · · · ·

History

UCLA David Geffen School of Medicine/UCLA Medical Center
Present

Hematology and Medical Oncology
Hospital of the University of Pennsylvania
2015–2018
Hospital of the University of Pennsylvania
2012–2015
University of Pennsylvania
Villanova University
2010–2014
The Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania
2008–2012

Research

Ribociclib plus Endocrine Therapy in Early Breast Cancer
New England Journal of Medicine · 2024 · 357 citations
Advances in Targeted Therapies for Triple-Negative Breast Cancer
Review · Drugs · 2019 · Last of 3 authors · 61 citations
Challenges in the clinical utility of the serum test for HER2 ECD
Review · Biochimica et Biophysica Acta · 2012 · 56 citations

Angela DeMichele
5 papers
Sara Hurvitz
5 papers
Aditya Bardia
4 papers
Amy Clark
3 papers
Karissa Britten
3 papers · 3 as a fellow
Angela Bradbury
2 papers
Dennis Slamon
2 papers
Eric Yang
2 papers
Kevin Fox
2 papers
Michael Feldman
2 papers
Peter O'Dwyer
2 papers
Richard Finn
2 papers

Clinical trials

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
Principal investigator · Active not recruiting · Phase 1, Phase 2
Jonsson Comprehensive Cancer Center
2022–2028
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
Principal investigator · Recruiting · Phase 2
Jonsson Comprehensive Cancer Center
2020–2026
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Site PI · Recruiting · Phase 2
Eli Lilly and Company
2026–2029
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2033